Ondine Biomedical Inc - Asset Resilience Ratio

Latest as of September 2008: 39.85%

Ondine Biomedical Inc (OBI) has an Asset Resilience Ratio of 39.85% as of September 2008. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

GBX1.88 Million
≈ $228.22 USD Cash + Short-term Investments

Total Assets

GBX4.71 Million
≈ $572.65 USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2007)

This chart shows how Ondine Biomedical Inc's Asset Resilience Ratio has changed over time. Check Ondine Biomedical Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Ondine Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ondine Biomedical Inc (OBI) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX1.88 Million 39.85%
Total Liquid Assets GBX1.88 Million 39.85%

Asset Resilience Insights

  • Very High Liquidity: Ondine Biomedical Inc maintains exceptional liquid asset reserves at 39.85% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Ondine Biomedical Inc Industry Peers by Asset Resilience Ratio

Compare Ondine Biomedical Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Prostemics Co. Ltd
KQ:203690
Biotechnology 0.31%
ORUM
KQ:475830
Biotechnology 82.74%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
TG Therapeutics Inc
NASDAQ:TGTX
Biotechnology 4.72%
Green Cross Holdings Preference Shares
KO:005257
Biotechnology 0.50%
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 33.70%
NEWRON PHARMACEUT. EO-20
XETRA:NP5
Biotechnology 41.67%
Cybin Inc
NEO:CYBN
Biotechnology 0.21%

Annual Asset Resilience Ratio for Ondine Biomedical Inc (2006–2007)

The table below shows the annual Asset Resilience Ratio data for Ondine Biomedical Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2007-12-31 43.12% GBX5.61 Million
≈ $682.19
GBX13.00 Million
≈ $1.58K
-15.66pp
2006-12-31 58.78% GBX10.85 Million
≈ $1.32K
GBX18.46 Million
≈ $2.25K
--
pp = percentage points

About Ondine Biomedical Inc

LSE:OBI UK Biotechnology
Market Cap
$821.79K
GBX6.75 Billion GBX
Market Cap Rank
#30670 Global
#841 in UK
Share Price
GBX13.00
Change (1 day)
+0.00%
52-Week Range
GBX8.00 - GBX18.00
All Time High
GBX58.50
About

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more